Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tamiflu Resistance Detected In Vietnamese Bird Flu Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Oseltamivir manufacturer Roche asserts that it maintains several monitoring mechanisms to evaluate efficacy of the antiviral.

You may also be interested in...



Roche Will Sell Tamiflu Under Tiered Pricing System For Pandemic Use

The firm names Shanghai Pharmaceutical Group as the first sub-licensee of the antiviral oseltamivir.

“Pharmaco-Metabonomics” Holds Promise for Personalized Drug Therapies, Researchers Say

The method uses a combination of advanced chemical analysis and mathematical modeling to predict drug response.

NCI-Funded Researchers Are Patenting At Surprisingly High Rate, Report Says

More than one in four National Cancer Institute-funded scientists start their own healthcare companies based on their own discoveries.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel